BioPorto A/S
Tuborg Havnevej 15, ground floor
DK-2900 Hellerup
Denmark
CVR DK-17500317

November 19, 2025
Announcement no. 26

BioPorto Interim Result for the Third Quarter of 2025 – Continued progress and continued NGAL sales growth.

Copenhagen, Denmark, November 19, 2025, (GLOBE NEWSWIRE) – BioPorto A/S ("BioPorto" or the "Company") (CPH:BIOPOR), today announced interim financial results for the third quarter of 2025, unchanged from the pre-announced Key Financial Results that were announced on November 4, 2025.

Highlights of key strategic milestones and a renewed strategy, "Forward"

- Delivery of the first ProNephro AKI™ (NGAL) order to the US market in August 2025, marking the first step in the commercial launch.
- At the end of October 2025, BioPorto successfully completed patient enrollment in its clinical cut-off study. As announced previously, the Company has decided to submit a pre-submission meeting request to the US Food and Drug Administration (FDA) once the dataset has been analyzed, now expectedly in Q1 2026. The clinical validation study is scheduled to begin following feedback from FDA, allowing BioPorto to proceed with a protocol aligned with FDA feedback. Accordingly, the FDA regulatory submission is postponed from the end of 2026 and into H1 2027.
- An updated strategy, "Forward" with focus on building market adoption, capturing high growth and expand addressable market was established. BioPorto's purpose to "improve kidney health and quality of lives" remains intact.
- On November 13, 2025, BioPorto announced a fully subscribed private placement of 40,438,426 new shares at market price. The offering is expected to provide gross proceeds of approximately DKK 43 million.

Carsten Buhl, BioPorto's Group Chief Executive Officer (CEO), comments:

"In the third quarter of 2025 we delivered the first US order of ProNephro AKI (NGAL) which marks the first step in building a commercial platform to drive broad adoption of ProNephro AKI through strategic distributors.

As we successfully completed patient enrollment and now are focusing on thorough data analysis, our commitment is to ensure the highest quality and most effective design for the validation study. While this means our FDA submission will shift into the first half of 2027, this approach derisks our design of the validation study.

Our "Forward" strategy represents a bold step in advancing our ambition to transform kidney care worldwide. By focusing our execution over the next three years, we are confident we can accelerate adoption, drive innovation, and improve outcomes for patients, all while staying true to our purpose.

Finally, on November 13, we successfully completed a share issuance, providing gross proceeds of approximately DKK 43 million. We greatly appreciate the strong support from both existing shareholders and new institutional and private investors, supplemented by a strong commitment from BioPorto's Board and management. The proceeds are projected to cover spending throughout 2026 and thereby position the Company strongly for its journey towards positive cash flow in the second half of 2027. "

Key Financial Results for the third quarter of 2025 and for the first nine months of 2025

- Revenue in the third quarter of 2025 totaled DKK 10.4 million, representing a 7% increase compared to the same period last year, and a 10% increase at constant exchange rates. For the first nine months of 2025 total revenue amounted to DKK 28.7 million, representing a 1% increase compared to the same period last year. At constant exchange rates the total revenue increased by 2%.
- For the third quarter of 2025, total NGAL sales totaled DKK 7.2 million, growing by 5% globally, and by 10% at constant exchange rates. For the first nine months of 2025, total NGAL sales rose by 5% compared to the first nine months of 2024 and by 7% at constant exchange rates.

- Adjusted EBITDA loss in the third quarter of 2025 amounted to DKK 16.8 million as expected, compared to DKK 19.6 million in the third quarter last year. For the first nine months of 2025 Adjusted EBITDA loss amounted to DKK 63.3 million, compared to DKK 51.1 million in the same period last year.
- As of September 30, 2025, the Company's cash position was in line with expectations, DKK 27.6 million compared to DKK 77.1 million in the same period last year.

Guidance

Based on the results for the first 9 months of 2025, the full-year guidance for 2025 is unchanged compared to previously announcement on November 4, 2025 where the company revised the 2025 Guidance to:

- Total revenue is expected to be in the range of DKK 40-45 million.
- Adjusted EBITDA loss is expected to be in the range of DKK 75-80 million.

In connection with the release of the Interim Report for the third quarter of 2025, the Company will host an online investor presentation on November 19, 2025, at 11:00 CET via HC Andersen Capital. Investors interested in attending the webcast may register here: BioPorto – Presentation of Q3 2025 Interim Results

To receive BioPorto's Company Announcements, Press Releases, Newsletters and other business relevant information, please sign up on Investor_contact.

Investor Relations Contacts

Niels Høy Nielsen, Chief Financial Officer, BioPorto A/S, investor@bioporto.com, C: +45 2551 8724

About BioPorto

BioPorto is an in vitro diagnostics company focused on saving patients' lives and improving their quality of life with actionable kidney biomarkers – tools designed to help clinicians make changes in patient management. The Company leverages its expertise in assay development to create a pipeline of novel and compelling products that focus on conditions where there is significant unmet medical need, and where the Company's tests can help improve clinical and economic outcomes for patients, providers, and the healthcare ecosystem.

The Company's flagship products are based on the NGAL biomarker and designed to aid in risk assessment and management of Acute Kidney Injury (AKI), a common clinical syndrome that can have severe consequences, including significant morbidity and mortality, if not identified and treated early. With the aid of NGAL levels, physicians can identify patients at risk of AKI more rapidly than is possible with current standard of care measurements, enabling earlier intervention and more tailored patient management strategies. The Company markets NGAL tests under applicable registrations including CE mark in several countries worldwide and FDA cleared ProNephro AKI™ (NGAL) in the US.

BioPorto has facilities in Copenhagen, Denmark and Boston, MA, USA. The shares of BioPorto A/S are listed on the Nasdaq Copenhagen stock exchange. For more information visit www.bioporto.com.

Forward looking statement disclaimer

Certain statements in this news release are not historical facts and may be forward-looking statements. Forward-looking statements include statements regarding the intent, belief or current expectations with respect to the Company's expectations, intentions and projections regarding its future performance including the Company's Guidance for 2025; currency exchange rate fluctuations; anticipated events or trends and other matters that are not historical facts, including with respect to implementation of manufacturing and quality systems, commercialization of NGAL tests, and the development of future products and new indications; concerns that may arise from

additional data, analysis or results obtained during clinical trials; and, the Company's ability to successfully market both new and existing products. These forward-looking statements, which may use words such as "aim", "anticipate", "believe", "intend", "estimate", "expect" and words of similar meaning, include all matters that are not historical facts. These forward-looking statements involve risks, and uncertainties that could cause the actual results of operations, financial condition, liquidity, dividend policy and the development of the industry in which the Company's business operates to differ materially from the impression created by the forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. Given these risks and uncertainties, prospective investors are cautioned not to place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date of such statements and, except as required by applicable law, the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Factors that may impact BioPorto's success are more fully disclosed in BioPorto's periodic financial filings, including its Annual Report for 2024, with the Danish Financial Supervisory Authority, particularly under the heading "Risk Factors".

Consolidated Financial Highlights

DKK million (except where noted)	2025 Jul 1 – Sep 30 (Unaudited)	2024 Jul 1 – Sep 30 (Unaudited)	2025 Jan 1 – Sep 30 (Unaudited)	2024 Jan 1 – Sep 30 (Unaudited)	2024 Jan 1 - Dec 31
Revenue	10.4	9.7	28.7	28.3	36.2
Gross profit	7.7	6.7	19.7	20.8	24.5
Sales and marketing costs	6.8	10.2	20.0	25.2	30.2
Research and development costs	10.3	9.6	39.9	23.0	33.5
Administrative costs	13.6	8.4	31.9	26.8	36.2
Loss before financial items (EBIT)	(23.0)	(21.6)	(72.1)	(54.2)	(75.5)
Financial items, net	(0.3)	(0.7)	(2.2)	(0.5)	1.7
Loss before tax	(23.3)	(22.3)	(74.3)	(54.7)	(73.7)
Net loss	(23.3)	(20.9)	(68.8)	(50.3)	(68.2)
Comprehensive loss	(23.2)	(19.7)	(66.0)	(49.4)	(69.5)
Adjusted EBITDA	(16.8)	(19.6)	(63.3)	(51.1)	(70.6)
Non-current assets			14.6	8.1	12.1
Cash and cash equivalents			27.6	77.1	59.7
Current assets			53.5	100.8	83.9
Total assets			68.1	108.9	96.0
Equity			35.2	86.5	67.8
Non-current liabilities			4.9	3.0	7.8
Current liabilities			28.0	19.4	20.4
Total equity and liabilities			68.1	108.9	96.0
Cash flows from operating activities			(61.4)	(65.1)	(83.6)
Cash flows from investing activities			(0.4)	0.9	1.2
Of which investment in property, plant, and equipment			(1.4)	-	(0.4)
Cash flows from financing activities			29.9	75.2	75.5
Net cash flows			(31.9)	10.7	(6.9)
Revenue growth	7%	12%	1%	16%	17%
Gross profit percentage	74%	69%	69%	74%	68%
Equity ratio (solvency)	52%	79%	52%	79%	71%
Average number of employees	46	42	48	36	38
Number of shares at the end of the period (1,000)	454,670	429,670	454,670	429,670	429,670
Loss per share (EPS), DKK	(0.05)	(0.05)	(0.15)	(0.13)	(0.17)
Net asset value per share, period-end, DKK	0.08	0.20	0.08	0.20	0.16
Share price, period-end, DKK	1.30	1.87	1.30	1.87	1.55

Note: Loss per share (EPS) is calculated in accordance with IAS 33 “Earning per share”. Other financial ratios have been calculated in accordance with the guidelines from the Danish Society of Financial Analysts and 2024 BioPorto Annual Report.

Reconciliation of Adjusted EBITDA					
Loss before financial items (EBIT)	(23.0)	(21.6)	(72.1)	(54.2)	(75.5)
Depreciation and amortization	0.6	0.6	1.9	1.8	2.4
Share-based compensation expenses	1.2	1.4	0.7	(2.3)	(0.9)
Severance costs	4.5	0.0	6.2	3.6	3.4
Adjusted EBITDA	**(16.8)**	**(19.6)**	**(63.3)**	**(51.1)**	**(70.6)**

Non-IFRS Financial Measure

In the Interim Report, BioPorto discloses a financial measure of the Group's financial performance that reflects adjustments to the most directly comparable measures calculated and presented in accordance with IFRS. This non-IFRS financial measure may not be defined and calculated by other companies in the same manner and may thus not be comparable.

The non-IFRS financial measure presented in the Interim Report is Adjusted earnings before interest, taxes, depreciation, and amortization (Adjusted EBITDA).

Adjusted EBITDA is an alternative measure of performance utilized by management, investors, and investment analysts to evaluate and analyze the Company's results. Adjusted EBITDA excludes non-cash share-based compensation and non-recurring costs (e.g., restructuring charges, merger and acquisition integration costs), if any. The company believe that earnings exclusive of non-cash and non-recurring costs is a key indication of how a company is progressing from period to period and that the non-IFRS financial measure Adjusted EBITDA is useful to investors, lenders, and other creditors because such information enables them to better understand earnings exclusive of non-cash and non-recurring costs from period to period. However, the company also believe that Adjusted EBITDA data has limitations, particularly as non-cash and non-recurring costs could significantly impact our performance. The company therefore limit the use of Adjusted EBITDA and do not evaluate our results and performance without considering both non-IFRS Adjusted EBITDA on the one hand and net income or loss on the other. The company caution the readers of this report to follow a similar approach by considering data on Adjusted EBITDA only in addition to, and not as a substitute for or superior to, net income or loss in accordance with IFRS.

Management Review

Revenue growth in the third quarter of 2025 driven by strong US NGAL RUO (Research Use Only) sales growth

Total Revenue for the third quarter of 2025 totaled DKK 10.4 million, a 7% increase compared to Q3 2024, and a 10% increase at constant exchange rates. Total NGAL sales rose by 5%, and by 10% at constant exchange rates, compared to the third quarter of 2024, driven by a 20% increase in US NGAL RUO sales and ProNephro AKI™ sales of DKK 2.1 million. Assuming constant exchange rates, US NGAL sales increased by 27%. NGAL sales for the rest of the world decreased by 87%.

Revenue in the third quarter of 2025 from antibodies sales rose by 17% and sales of ELISA kits decreased by 11% compared to the third quarter of 2024.

DKK million	Q3 2025	Q3 2024	Var	9M 2025	9M 2024	Var
US NGAL	4.7	3.9	20%	13.6	11.2	21%
ROW NGAL	0.4	2.8	-87%	3.6	7.1	-49%
ProNephro AKI (distributors)	2.1	-	-	2.1	-	-
NGAL Total	**7.2**	**6.8**	**5%**	**19.3**	**18.3**	**5%**
Antibodies	2.9	2.5	17%	8.2	8.4	-3%
ELISA & other	0.4	0.4	-11%	1.2	1.6	-22%
Total Revenue	**10.4**	**9.7**	**7%**	**28.7**	**28.3**	**1%**

Total Revenue for the first nine months of 2025 totaled DKK 28.7 million, a 1% increase compared to the first nine months of 2024, and a 2% at constant exchange rates. Total NGAL sales rose by 5% compared to the first nine months of 2024, and by 10% at constant exchange rates, driven by a 21% increase in US NGAL sales and ProNephro AKI™ sales of DKK 2.1 million. Assuming constant exchange rates, US NGAL sales increased by 23%. NGAL sales for the rest of the world decreased by 49%. Revenue in the first nine months of 2025 from antibodies sales declined by 3% compared to the first nine months of 2024.

BioPorto delivered the first ProNephro AKI™ order for the US market

The key highlight for the third quarter of 2025 was the delivery of the first ProNephro AKI (NGAL) order to our distributor for the US market in August 2025. This represents a significant milestone and the first commercial step in BioPorto's ambition to establish a commercial platform for kidney diagnostics and to drive broader adoption of ProNephro AKI.

The next phase involves submission of ProNephro AKI (NGAL) for other Cobas® analyzers than the c 501 to the FDA. BioPorto is also working to expand the global distribution network through partnerships with other instrument manufacturers. These efforts aim to accelerate the adoption of NGAL-cleared instruments, broaden test availability across laboratories, and significantly increase the addressable market — laying the foundation for pediatric and adult indication available across multiple instruments.

Preparation of FDA application for ProNephro AKI (NGAL) for adults

The enrollment of patients in the US clinical cut-off study for ProNephro AKI (NGAL) has been completed at the end of October 2025.

The goal of the cut-off study is to determine a cut-off point for risk stratification of moderate to severe AKI in adult patients. The cut-off study is the first of two studies which will form a substantial part of the adult submission for US clearance of ProNephro AKI (NGAL). Currently, the study data is being collected, and this process is taking more time than initially anticipated.

To ensure the most effective design of the validation study, a pre-submission to the FDA is intended once the full dataset is available.

As a result, the validation study is now scheduled to begin following feedback from FDA. This allows us to proceed with greater precision and alignment with regulatory expectations. The timeline for the adult submission for US FDA clearance is postponed to the first half of 2027.

BioPorto still expects the FDA submission could lead to a clearance for clinical use in adult patients in 2027, allowing the test to be commercially distributed to this segment in the US.

BioPorto's "Forward" Strategic Direction

As commercial opportunities in the US begin to materialize, BioPorto has transitioned from a research-based organization to a growth-oriented company. To lead the business in the next phases of commercialization and towards FDA clearance of ProNephro AKI (NGAL) for adult use in 2027, Carsten Buhl assumed the role of Chief Executive Officer (CEO), effective September 1, 2025.

Following a review of the company's strategic direction, a revised plan was presented at the beginning of November. BioPorto's purpose to "improve kidney health and quality of lives of patients" remains intact, as well as its ambition to pursue its purpose: "Through actionable biomarkers enabling clinicians to know earlier, manage better with confidence and thereby transform kidney care globally". The "Forward" strategic plan focuses on building market adoption, capturing high growth and expand addressable market.

2026	2027	2028
Build **Market Adoption** for BioPorto's NGAL test	Capturing **High Growth** within the addressable Market of USD 700m	Expand **Addressable Market** & accelerate growth
• Increase market adoption • Reach 60+ active hospitals in the US • Initiate the clinical validation study for adults	• Increase market adoption in the EU • Reach +100 active hospitals globally • FDA submission for adults by first half of 2027 & CE-mark under EU IVDR in 2027	• Expand the market adoption in the EU • Reach +170 active hospitals globally • Unlock broader market potential by targeting new patients' segments

Following BioPorto's revised "Forward" strategic plan, the company has revised its financial guidance for 2025 and aspirations for the next three years.

Aspirations	Update – Nov 2025 (Replaces Feb 2024 aspiration)	Previously Feb 2024
Cash flow positive	Second half of 2027	End 2026 at the earliest
Revenue	DKK 150-200 million FY 2028	USD 100 million FY 2029
Adj. EBITDA-margin	+15% FY 2028	Neutral end 2026 at the earliest

Ongoing funding considerations

To support the previously announced estimated funding needs of DKK 60 – 70 million until cash flow positive in second half of 2027, the Company announced on November 13, 2025, the completion of a fully subscribed private placement of 40,438,426 new shares at market price, providing gross proceeds of approximately DKK 43 million. The proceeds will finance completing data collection, submitting a pre-submission to the FDA, and initiating the Validation Study in BioPorto's U.S. clinical trial, while strengthening our commercial platform. The proceeds are projected to cover spending throughout 2026 and thereby position the Company strong for its journey towards positive cash flow in the second half of 2027.

Financial Review

This financial review is based on the Group's consolidated financial information for the third quarter and the first nine months of 2025 ended September 30, 2025, with comparative results for the third quarter and the first nine months of 2024 ended September 30, 2024, in brackets.

Revenue

Revenue totaled DKK 10.4 million (DKK 9.7 million) in the third quarter of 2025, increasing 7% over prior period, mainly due to increased NGAL test sales. In the third quarter NGAL test sales totaled DKK 7.2 million (DKK 6.8 million), growing 5% due to an increase of 20% in NGAL US RUO sales, a decrease of 87% in NGAL ROW sales and ProNephro AKI distribution sale of DKK 2.1 million compared to the prior year period. Antibody sales totaled DKK 2.9 million (DKK 2.5 million), increasing by 17%.

Figure 1. Revenue by quarter (DKK million)



Figure 2. NGAL test product revenue by quarter (DKK million)



In the first nine months of 2025 revenue totaled DKK 28.7 million (DKK 28.3 million), increasing 1%. For the first nine months of 2025 NGAL test sales totaled DKK 19.3 million (DKK 18.3 million), growing 5%, which comprised 67% of total revenue. US NGAL RUO revenue totaled DKK 13.6 million (DKK 11.2 million), growing 21%, while NGAL revenue in ROW declined by 49% to DKK 3.6 million (DKK 7.1 million) and ProNephro AKI distribution revenue of DKK 2.1 million. Further, the Antibody sales declined by 3% to DKK 8.2 million (DKK 8.4 million).

Gross Profit

Gross profit for the third quarter of 2025 was DKK 7.7 million (DKK 6.7 million), the increase was driven by higher sales volume and lower staff costs in Production compared to prior year period.

Gross profit for the first nine months of 2025 was DKK 19.7 million (DKK 20.8 million), the decrease was mainly driven by higher consultancy costs and increased staff costs in first half of 2025 in production compared to prior year period.

Sales and Marketing Costs

Sales and marketing costs totaled DKK 6.8 million (DKK 10.2 million) in the third quarter of 2025. The decrease in sales and marketing costs was primarily driven by reversal of share-based compensation expenses and lower recruiting and consultancy costs.

Sales and marketing costs totaled DKK 20 million (DKK 25.2 million) in the first nine months of 2025. The decrease was primarily driven by reversal of share-based compensation expenses and lower recruiting and consultancy costs; offset by the carry-over from end of 2024 of staffing up in areas of business development and sales force to commercialize ProNephro AKI (NGAL) in the US.

Research and Development Costs

Research and development costs, consisting of research and development, regulatory affairs, quality assurance, clinical, and medical affairs, totaled in the third quarter of 2025 DKK 10.3 million (DKK 9.6 million), with the increase mainly due to our adult clinical study.

For the first nine months of 2025, these costs amounted to DKK 39.9 million (DKK 23.0 million), also primarily driven by our adult clinical study.

Administrative Costs

Administrative costs in the third quarter of 2025 totaled DKK 13.6 million (DKK 8.4 million). The increase in costs is due to severance costs and additional staff being hired during the first nine months of 2025.

Administrative costs in the first nine months of 2025 totaled DKK 31.9 million (DKK 26.8 million). The increase in costs is due to severance costs that incurred in the third quarter of 2025.

Financials Items, net

Financial income and expenses reflect interest income/expense and currency transaction gains/losses. Financial items, net for the third quarter of 2025 were an expense of DKK 0.3 million (income of DKK 0.1 million), and expense of DKK 2.2 million (income of DKK 0.4 million) in the first nine months of 2025.

Tax Benefit

In the third quarter of 2025, a DKK 0 million tax benefit (DKK 1.4 million) was recognized as the company in Q2 2025 reached the cap for the year of the tax benefit. For the first nine months of 2025 DKK 5.4 million (DKK 4.4 million) was recognized. The tax benefit is primarily related to tax credits held by the company's Danish entities associated with the Company's investment in research and development.

EBIT/Adjusted EBITDA

For the third quarter of 2025, Earnings before interest and taxes (EBIT) was a loss of DKK 23.0 million (DKK 21.6 million), and adjusted EBITDA was a loss of DKK 16.8 million (DKK 19.6 million).

For the first nine months of 2025, Earnings before interest and taxes (EBIT) was a loss of DKK 72.1 million (DKK 54.2 million), and adjusted EBITDA was a loss of DKK 63.3 million (DKK 51.1 million).

Cash and Cash equivalents

As of September 30, 2025, BioPorto's cash position was DKK 27.6 million (DKK 77.1 million).

The Company regularly reviews its cash needs, funding plans and available resources based on operations and further goals. This review depends on key assumptions and judgments, which are used in the budgets and forecasts.

The Company assessed its liquidity and capital resources based on the current cash position if no additional financing is to be added in the next four quarters and concluded that these are adequate to fund operations considering a twelve-month period from the balance sheet date. The Company has continuously exercised strong cost control to preserve cash in the first nine months of 2025.

Net working capital

Net working capital (i.e., current assets minus current liabilities) as of September 30, 2025, totaled DKK 25.5 million (DKK 81.4 million).

Cash Flow Statement

Cash used in operating activities during the first nine months of 2025 totaled DKK 61.4 million (DKK 65.3 million), driven by the EBIT loss explained in the sections above.

Cash used in investing activities was DKK 0.4 million (inflow of DKK 0.9 million). Cash from financing activities was DKK 29.9 (DKK 75.2 million), reflecting DKK 32.8 million net proceeds from the directed offering completed in April 2025.

The net cash flow during the first nine months of 2025 was a use of DKK 31.9 million (source of DKK 10.7 million).

Subsequent event

Please see Note 13 for further details.

Significant risks and uncertainties

BioPorto faces a number of risks and uncertainties, including those common for the biotech/medical device industry and could potentially impact the Company across the value chain including clinical and regulatory, research and development, manufacturing, commercial, and financial activities. Furthermore, the uncertainty in the US could impact the Company adversely by implementation of tariffs or delaying any submissions with the FDA.

A variety of factors and events, including geopolitical uncertainty, have resulted in delays and other challenges in global supply chains. To manufacture its products, the Company is dependent on the supply of raw materials and key components from suppliers, some of which are single source suppliers. Delays in the manufacturing, delivery, or quality of these components, or delays in the Company's execution of its commercialization strategy, including hiring personnel and continuing to prepare manufacturing and quality systems, could affect the Company's ability to deliver products to its customers, which could cause the Company's results, prospects, and financial performance to be negatively impacted.

In addition, a full description of risks can be found in BioPorto's 2024 Annual Report in the section captioned "Risk Management", describing which factors could materially affect the Group's business, financial condition, and/or future results. The risks described in those sections and in this report are not the only risks BioPorto faces. Additional risks and uncertainties not currently known to management or the Group or that the Group currently deems to be immaterial may also have a material adverse effect on the Group's business, future opportunities, financial condition, and/or operating results.

Guidance 2025

Based on the results for the first nine months of 2025 and the outlook for the remaining part of 2025, the company announced November 4, 2025 that the company revised the financial guidance. As previously announced the Guidance is as follows:

Total Revenue is expected to be in the range DKK 40-45 million. Sales for the remaining part of 2025 are still expected to be back-end loaded.

Adjusted EBITDA loss is expected to be in the range DKK 75-80 million.

Forward-looking safe harbor statements

This interim report contains forward-looking statements that involve risks, uncertainties, and other factors, many of which are outside of BioPorto's control, that could cause actual results to differ materially from the results or expectations discussed in the forward-looking statements. Forward-looking statements include statements concerning the Group's plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. BioPorto does not undertake any obligation to update or revise forward-looking statements to reflect subsequent events or circumstances after the date made.

For Further Information

Niels Høy Nielsen, Chief Financial Officer, BioPorto, +45 4529 0000,
investor@bioporto.com
www.bioporto.com

Statement by the Board of Directors and Management

The Board of Directors and Executive Management today reviewed and approved the Interim Report of the BioPorto Group for the period January 1 to September 30, 2025.

The Interim Report, which is unaudited and has not been reviewed by the Company's auditors, is presented in accordance with IAS 34 "Interim Financial Reporting" as adopted by the EU and additional Danish disclosure requirements for interim reports of listed companies.

In our opinion, the interim report gives a true and fair view of the Group's financial position as of September 30, 2025, and the results of the Group's operations and cash flows for the period January 1 to September 30, 2025.

In our opinion the management's review includes a fair review of the development and performance of the business, the results for the period and the Group's financial position in general and describes changes in principal risks and uncertainties that have occurred relative to what was disclosed in the consolidated Annual Report for 2024.

Hellerup, November 19, 2025

Executive Management:

_____	_____	_____
Carsten Buhl	**Gry Louise Husby Larsen**	**Niels Høy Nielsen**
CEO	CLO	CFO

Board of Directors:

_____	_____	_____
Jens Due Olsen	**Henrik Juuel**	**Mats Thorén**
Chair	Vice Chair	

_____

Donna Haire

Interim Financial Statements (unaudited)

Consolidated Statements of Loss

DKK thousand	Notes	2025 Jul 1 - Sep 30 (Unaudited)	2024 Jul 1 - Sep 30 (Unaudited)	2025 Jan 1 - Sep 30 (Unaudited)	2024 Jan 1 - Sep 30 (Unaudited)	2024 Jan 1 - Dec 31
Revenue	3	10,406	9,685	28,664	28,346	36,243
Production costs		2,706	3,003	8,995	7,511	11,713
Gross profit		**7,700**	**6,682**	**19,669**	**20,835**	**24,530**
Sales and marketing costs		6,812	10,248	19,960	25,171	30,202
Research and development costs		10,264	9,620	39,889	23,025	33,533
Administrative costs		13,618	8,416	31,920	26,816	36,247
Loss before financial items (EBIT)		**(22,994)**	**(21,602)**	**(72,100)**	**(54,177)**	**(75,452)**
Financial income		83	316	432	1,036	2,543
Financial expenses		402	1,034	2,589	1,523	834
Loss before tax		**(23,313)**	**(22,320)**	**(74,257)**	**(54,664)**	**(73,743)**
Income tax benefit, net	5	-	1,434	5,422	4,382	5,500
Net loss		**(23,313)**	**(20,886)**	**(68,835)**	**(50,282)**	**(68,243)**
				DKK		DKK
Loss per share (EPS & DEPS)	6	(0.05)	(0.05)	(0.15)	(0.13)	(0.17)

Consolidated Statements of Comprehensive Loss

DKK thousand	2025 Jul 1 - Sep 30 (Unaudited)	2024 Jul 1 - Sep 30 (Unaudited)	2025 Jan 1 - Sep 30 (Unaudited)	2024 Jan 1 - Sep 30 (Unaudited)	2024 Jan 1 - Dec 31
Net loss	**(23,313)**	**(20,886)**	**(68,835)**	**(50,282)**	**(68,243)**
Other comprehensive loss:					
Amounts which will be reclassified to the income statement:					
Exchange rate adjustments of investments in subsidiaries	163	1,229	2,811	920	(1,277)
Other comprehensive loss	**163**	**1,229**	**2,811**	**920**	**(1,277)**
Comprehensive loss	**(23,150)**	**(19,657)**	**(66,024)**	**(49,362)**	**(69,520)**

Consolidated Balance Sheets

Assets

DKK thousand	Notes	2025 Sep 30 (Unaudited)	2024 Sep 30 (Unaudited)	2024 Dec 31
Non-current assets				
Property, plant and equipment and intangible assets				
Rights and software		173	311	276
Property, plant and equipment		1,641	551	2,136
Right-of-use assets		5,263	-	6,579
Total property, plant and equipment and intangible assets		**7,077**	**862**	**8,991**
Financial assets				
Lease receivable - Long term	9	682	1,541	1,707
Deposits		1,348	1,351	1,415
Non-current tax receivable	5	5,500	4,382	-
Total financial assets		**7,530**	**7,274**	**3,122**
Total non-current assets		**14,607**	**8,136**	**12,113**
Current assets				
Inventories		5,613	4,718	4,640
Trade receivables	7, 9	9,399	6,184	8,187
Current tax receivable	5	6,280	5,889	6,392
Other receivables	7, 9	1,328	2,326	1,368
Prepayments	7	2,163	3,407	2,448
Lease receivable - short term	9	1,107	1,146	1,200
Cash and cash equivalents	9	27,593	77,092	59,664
Total current assets		**53,483**	**100,762**	**83,899**
Total assets		**68,090**	**108,898**	**96,012**

Equity and Liabilities

DKK thousand	Notes	2025 Sep 30 (Unaudited)	2024 Sep 30 (Unaudited)	2024 Dec 31
Equity				
Share capital	8	454,670	429,670	429,670
Exchange-rate adjustments		1,759	1,145	(1,052)
Retained earnings		(421,247)	(344,270)	(360,840)
Total equity		**35,182**	**86,545**	**67,778**
Liabilities				
Non-current liabilities				
Lease obligations	9	4,941	2,952	7,846
Total non-current liabilities		**4,941**	**2,952**	**7,846**
Current liabilities				
Current portion of lease obligations	9	3,395	1,673	3,344
Trade payables	9	5,228	2,881	5,706
Tax payables		-	76	-
Other accrued liabilities	10	19,344	14,771	11,338
Total current liabilities		**27,967**	**19,401**	**20,388**
Total liabilities		**32,908**	**22,353**	**28,234**
Total equity and liabilities		**68,090**	**108,898**	**96,012**

Consolidated Statement of Changes in Equity

Amounts in DKK thousand	Share Capital	Share Premium	Accumulated Deficit	AOCI	Total
Balance at December 31, 2024	**429,670**	**-**	**(360,869)**	**(1,052)**	**67,750**
Other comprehensive loss	-	-	-	2,811	**2,811**
Transaction with owners:					
Issuance of stock	25,000	8,505	-	-	**33,505**
Issuance costs	-	(735)	-	-	**(735)**
Transferred to Accumulated Deficit	-	(7,770)	7,770	-	**-**
Share-based compensation	-	-	687	-	**687**
Net loss	-	-	(68,835)	-	**(68,835)**
Balance at September 30, 2025	**454,670**	**-**	**(421,247)**	**1,759**	**35,182**

Amounts in DKK thousand	Share Capital	Share Premium	Accumulated deficit	AOCI	Total
Balance at December 31, 2023	**379,670**	**-**	**(319,735)**	**225**	**60,160**
Other comprehensive loss	-	-	-	920	**920**
Transaction with owners:					
Issuance of stock	50,000	31,400	-	-	**81,400**
Issuance costs	-	(3,387)	-	-	**(3,387)**
Transferred to Accumulated Deficit	-	(28,013)	28,013	-	**-**
Share-based compensation	-	-	(2,266)	-	**(2,266)**
Net loss	-	-	(50,282)	-	**(50,282)**
Balance at September 30, 2024	**429,670**	**-**	**(344,270)**	**1,145**	**86,545**

Consolidated Statement of Cash Flows

DKK thousand	Notes	2025 Jan 1 - Sep 30 (Unaudited)	2024 Jan 1 - Sep 30 (Unaudited)	2024 Jan 1 - Dec 31
Loss before financial items		**(72,100)**	**(54,177)**	**(75,452)**
Adjustments:				
Depreciation and amortization		1,914	1,768	2,382
Share based compensation expenses	4	687	(2,266)	(875)
Other non-cash items		1,339	1,854	(1,400)
Remeasurement of lease		-	-	(984)
Changes in operating assets and liabilities:				
Inventories		(1,127)	(750)	(864)
Trade receivables		(1,238)	(3,836)	(5,847)
Trade payables		(478)	(4,024)	(1,199)
Other operating assets and liabilities, net		9,562	(3,665)	(5,542)
Cash flows from operations		**(61,441)**	**(65,096)**	**(89,781)**
Financial income, received		196	92	1,641
Financial expenses, paid		(144)	(328)	(381)
Tax refund, net		-	-	4,938
Cash flows from operating activities		**(61,389)**	**(65,332)**	**(83,583)**
Purchase of property, plant and equipment		(1,368)	-	(350)
Purchase of financial assets		-	-	(165)
Proceeds from financial assets		-	-	921
Proceeds from sublease		974	892	781
Cash flows from investing activities		**(394)**	**892**	**1,187**
Proceeds from rights issue		33,505	81,400	81,400
Cost related to Issue of new shares		(735)	(3,387)	(3,387)
Repayments of lease obligation		(2,859)	(2,843)	(2,547)
Cash flows from financing activities		**29,911**	**75,171**	**75,466**
Net cash flows for the period		**(31,872)**	**10,730**	**(6,930)**
Cash and cash equivalents at beginning of period		59,664	66,402	66,402
Effect of exchange rate changes on cash		(199)	(40)	192
Cash and cash equivalents end of period		**27,593**	**77,092**	**59,664**

Notes to Interim Consolidated Financial Statements (Unaudited)

1. Basis of reporting

Basis of preparation

This Interim Report and the accompanying unaudited interim consolidated financial statements include the accounts of BioPorto A/S and its subsidiaries ("BioPorto" or "the Group"). All significant intercompany accounts and transactions have been eliminated in consolidation. The accompanying unaudited interim consolidated financial statements have been prepared in accordance with IAS 34 "Interim Financial Reporting" as issued by the International Accounting Standards Board (IASB) and adopted by the EU, and the additional Danish regulations for the presentation of quarterly interim reports by listed companies. Certain information and footnote disclosures normally included in the consolidated financial statements prepared in accordance with IFRS Accounting Standards ("IFRS") as adopted by the EU have been condensed or omitted pursuant to such rules and regulations. The accompanying unaudited interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto contained in BioPorto's Annual Report for the fiscal year ended December 31, 2024.

The Company's assessment as to the adequacy of liquidity relies inter alia on assumptions and significant judgements (in addition to those matters discussed cf. Note 2) applied in the Company's budgets and forecasts as well as customary sensitivities, existing capital resources and assumptions concerning the timing, costs and resources required to undertake the Company's strategic priorities and tactical decisions. The company has allocated resources and significant efforts regarding the US clinical commercial launch of ProNephro AKI (NGAL) for pediatric and young adults, commercialization activities for NGAL tests under CE Mark and Antibodies in Europe, supply chain management, and ongoing R&D, all of which under current circumstances remain difficult to predict.

The Company assessed its liquidity and capital resources based on the current cash position if no additional financing is to be added in the next four quarters and concluded that these are adequate to fund operations considering a twelve-month period from the balance sheet date. The Company continues to monitor its liquidity needs, manage its costs, and investigate its financing options.

In the event that the Company's strategic priorities and tactical decisions, commercialization activities for NGAL tests in the US, under CE Mark and Antibodies, and ongoing R&D are more positive than expected, the Company may choose to accelerate projects and/or increase spending, in which case the Company may be required or may choose to raise additional capital prior to the twelve month period after the date of this Interim Report.

The unaudited interim consolidated financial statements are presented in Danish Kroner (DKK), which is considered the primary currency of the Group's activities and the functional currency of the parent company.

Accounting policies

The accounting policies used in the unaudited interim consolidated financial statements are consistent with those used in the consolidated financial statements for 2024 and in accordance with the recognition and measurement policies of IFRS. Certain comparative figures have been reclassified to conform to the current period's presentation.

As of September 30, 2025, the Group has implemented all new or amended IFRS accounting standards and interpretations as adopted by the EU and applicable for the 2025 financial year. None of the new or amended standards or interpretations are assessed to have a material impact on the unaudited consolidated financial statements. The Group has not implemented any new or modified standards and interpretations that are not yet effective. The new or modified standards and interpretations will be implemented when they become mandatory. They are not presently expected to have a material impact on the Group's consolidated financial statements.

The new IFRS 18 is expected to change the presentation of the Income statement and to differentiate between earnings from operating activities, investment activities and financing activities. IFRS 18 will also add additional disclosures but will not change any accounting policies on recognition and measurement, hence it will not change reported net results. IFRS 18 will come into effect in 2027 or later.

2. Critical accounting estimates and judgments

The calculation of the carrying amounts of certain assets and liabilities requires an estimate of how future events will affect the value of such assets and liabilities at the balance sheet date. Estimates material to the financial reporting are made in the calculation of, *inter alia*, development costs, incentive schemes, inventories, accounts receivable, and deferred taxes.

The estimates made are based on assumptions that Management finds reasonable given the circumstances, but which are inherently uncertain and unpredictable. The assumptions may be incomplete or imprecise and unexpected events or circumstances may arise. In addition, the Company is subject to risks and uncertainties that may cause actual results to deviate from the estimates. Such estimates comprise judgments made on the basis of the most recent information available at the reporting date. It may be necessary to change previous estimates as a result of changes to the assumptions on which the estimates were based or due to supplementary information, additional experience or subsequent events.

Similarly, the value of assets and liabilities often depends on future events that are somewhat uncertain. In that connection, it is necessary to set out e.g., a course of events that reflects Management's assessment of the most probable course of events. Special risks to BioPorto are described in the Annual Report as of and for the year ended December 31, 2024. The significant judgements made by Management in applying the Group's accounting policies and the key sources of estimation uncertainty were not materially different from those that applied to the consolidated financial statements, C.f. the Annual Report as of and for the year ended December 31, 2024.

3. Business area reporting

GEOGRAPHIC DISTRIBUTION DKK Thousand	2025 Jul 1 - Sep 30 (Unaudited)	2024 Jul 1 - Sep 30 (Unaudited)	2025 Jan 1 - Sep 30 (Unaudited)	2024 Jan 1 - Sep 30 (Unaudited)	2024 Jan 1 - Dec 31
North America	6,194	5,363	17,887	15,077	20,634
Europe	3,615	1,458	7,896	8,194	10,237
Asia	597	2,864	2,881	5,075	5,372
Revenue	**10,406**	**9,685**	**28,664**	**28,346**	**36,243**

PRODUCT GROUPS DKK Thousand	2025 Jul 1 - Sep 30 (Unaudited)	2024 Jul 1 - Sep 30 (Unaudited)	2025 Jan 1 - Sep 30 (Unaudited)	2024 Jan 1 - Sep 30 (Unaudited)	2024 Jan 1 - Dec 31
NGAL tests	7,150	6,803	19,277	18,330	23,054
Antibodies	2,892	2,472	8,165	8,441	10,783
ELISA kits	262	402	1,077	1,521	2,269
Royalty and other revenue	102	8	145	54	137
Revenue	**10,406**	**9,685**	**28,664**	**28,346**	**36,243**

4. Share-based payment

For the purpose of motivating and retaining Management and key staff and aligning their interests with those of its shareholders, BioPorto A/S uses warrants as an incentive scheme. The arrangements, which are exercised by the issuance of new shares (equity-settled share-based payment transaction), entitle the recipient to subscribe for new shares in the parent company at a price defined on the date of grant.

In the first nine months of 2025, share-based compensation totaled an cost of DKK 0.7 million compared to an income of DKK 2.3 million for the same period in 2024. The warrant terms are included in the Company's Articles of Association, which can be found at www.bioporto.com. Upon vesting, each warrant entitles the recipient to subscribe for one share in BioPorto A/S.

5. Taxes

The Group has a deferred tax asset. However, Management has found that it is not sufficiently probable that the tax asset can be utilized in the foreseeable future. Management has therefore decided not to recognize the deferred tax assets on the balance sheet, cf. Note 2. The deferred tax asset is of indefinite duration. As of the most recent year-end, December 31, 2024, the gross value of the deferred tax asset prior to the valuation allowance was DKK 105.4 million.

Taxes receivable represent refunds of previous US federal tax liabilities and tax credits held by its Danish entities associated with the Company's investment in research and development.

6. Loss per share

DKK thousand (except where noted)	2025 Jul 1 - Sep 30 (Unaudited)	2024 Jul 1 - Sep 30 (Unaudited)	2025 Jan 1 - Sep 30 (Unaudited)	2024 Jan 1 - Sep 30 (Unaudited)	2024 Jan 1 - Dec 31
Loss for the period	(23,313)	(20,886)	(68,835)	(50,282)	(68,243)
BioPorto Group's share of loss	**(23,313)**	**(20,886)**	**(68,835)**	**(50,282)**	**(68,243)**
Weighted average number of shares (in thousand)	454,670	429,670	444,231	397,736	405,763
Weighted average number of treasury shares (in thousand)	(13)	(13)	(13)	(13)	(13)
Weighted average number of shares in circulation – basic and diluted (in thousand)	454,657	429,657	444,218	397,723	405,750
Loss per share (EPS) basic and diluted, DKK	**(0.05)**	**(0.05)**	**(0.15)**	**(0.13)**	**(0.17)**

Warrants outstanding were excluded from the calculation of loss per share because the effect would have been anti-dilutive.

7. Receivables

For receivables that mature within one year after the end of the financial year, the nominal value is considered to correspond to the fair value.

DKK thousand	2025 Sep 30 (Unaudited)	2024 Sep 30 (Unaudited)	2024 Dec 31
Trade receivables	9,489	6,240	8,251
Other receivables	1,328	2,326	1,368
Prepayments	2,163	3,407	2,448
Write-down for bad debt	(90)	(56)	(64)
Receivables at amortized costs	**12,890**	**11,917**	**12,003**

A write-down for bad debts is recognized to reduce the carrying amount of trade receivables by the value which is impaired due to risk of loss.

AS OF SEPTEMBER 30, 2025

DKK thousand	Expected credit loss rate	Trade receivables	Expected loss	Total
Not due	0.1%	7,403	7	7,396
1 - 30 days overdue	0.1%	741	1	740
31 - 60 days overdue	0.6%	462	3	459
61 - 90 days overdue	0.0%	232	1	231
More than 90 days overdue	12.0%	651	78	573
As of September 30, 2025		**9,489**	**90**	**9,399**

AS OF SEPTEMBER 30, 2024

DKK thousand	Expected credit loss rate	Trade receivables	Expected loss	Total
Not due	0.4%	5,803	22	5,781
1 - 30 days overdue	0.3%	360	1	359
31 - 60 days overdue	0.0%	16	-	16
61 - 90 days overdue	0.0%	0	-	0
More than 90 days overdue	54.1%	61	33	28
As of September 30, 2024		**6,240**	**56**	**6,184**

8. Share capital

As of September 30, 2025, the share capital consists of 454,670,461 shares of DKK 1.00 each. The share capital has been paid up in full. The shares have not been divided into classes and carry no special rights.

9. Financial risks and financial instruments

Financial instrument categories

DKK thousand	2025 Sep 30 (Unaudited)	2024 Sep 30 (Unaudited)	2024 Dec 31
Trade receivables	9,399	6,184	8,187
Other receivables	1,328	2,326	1,368
Lease receivable - Short term	1,107	1,146	1,200
Lease receivable - Long term	682	1,541	1,707
Cash and cash equivalents*	27,593	77,092	59,664
Financial assets at amortized costs	**40,109**	**88,289**	**72,126**

*As of September 30, 2025 DKK 1,510 thousand are restricted cash against third-party delivery of goods (DKK 750 thousand as per Sep. 30, 2024 and DKK 0 thousand as per Dec. 31, 2024)

DKK thousand	2025 Sep 30 (Unaudited)	2024 Sep 30 (Unaudited)	2024 Dec 31
Lease liabilities	8,336	4,625	11,190
Trade payables	5,228	2,881	5,706
Financial liabilities at amortized costs	**13,564**	**7,506**	**16,896**

Financial liabilities

Trade payables generally fall due within one year after the end of the financial year. Their carrying amount is assumed to equal the fair value.

Currency risk

The Group's presentation currency is DKK, but part of its activities is denominated in currencies other than DKK, primarily USD and EUR. Consequently, there is a risk of exchange rate fluctuations having an impact on the Group's reported results.

The Group is exposed to currency risks through sales, production, R&D contracts, and payroll denominated in currencies other than DKK. The Group is subjected to transaction risk related to sales and purchases in foreign currencies, and translation risk when translating foreign entities into the Group's presentation currency.

B/S CURRENCIES PERCENTAGES DKK thousand	2025 Sep 30 (Unaudited)	2024 Sep 30 (Unaudited)	2024 Dec 31
Inventory			
DKK	100%	100%	100%
Trade receivables			
USD	25%	30%	30%
EUR	72%	69%	68%
Other	3%	1%	2%
Cash and cash equivalents			
DKK	68%	96%	93%
USD	19%	4%	6%
EUR	13%	-	1%
Trade payables			
DKK	16%	53%	53%
USD	77%	31%	29%
EUR	7%	16%	17%
Other	0%	0%	1%

Based on its transaction volume, the Group has determined not to hedge its USD exposure. As the DKK is pegged to the EUR, hedging of the Company's transactions in EUR is not necessary.

Interest rate risk

The Group has interest rate exposure because substantially all of its assets consist of bank deposits. A one percent change in interest rate could result in a change in interest income of approximately DKK 0.3 million based on the interest-bearing accounts portion of the DKK 27.6 million cash and cash equivalents as of September 30, 2025.

Credit risk

The Group's credit risk is primarily associated with trade receivables. Cash and cash equivalents are deposited with major Nordic and US banks. The financial situation and ability of customers to pay trade receivables are regularly evaluated, with payment upon placement of an order required if ability-to-pay is evaluated to be low. Expected credit losses are estimated by analyzing trade receivables by customer type and days past due. An estimated loss percentage is calculated based on historical credit losses and specific customer circumstances. Trade receivables are written off when there is no reasonable expectation of recovery.

Liquidity risk

In connection with BioPorto's ongoing financing of operations, efforts are made to ensure sufficient financial resources are available. BioPorto's cash and cash equivalents totaled DKK 27.6 million as of September 30, 2025 and DKK 59.7 million as of December 31, 2024, respectively.

Free funds are placed in deposits to maintain flexibility.

Capital structure

Management regularly assesses whether the Group's capital structure properly serves the interests of the Group and its shareholders.

10. Other accrued liabilities

DKK thousand	2025 Sep 30 (Unaudited)	2024 Sep 30 (Unaudited)	2024 Dec 31
Accrued incentive compensation	2,920	5,600	3,290
Accrued vacation	1,500	1,861	1,599
Accrued professional and consulting fees	1,853	1,473	1,014
Accrued clinical trial costs	5,428	328	892
Accrued supplier costs	2,415	2,445	2,926
Accrued staff costs liabilities	-	436	-
Accrued severance costs	4,000	1,076	-
Accrued expenses - Other	1,228	1,552	1,617
Other accrued liabilities	**19,344**	**14,771**	**11,338**

11. Commitments and contingencies

All of the Company's existing and proposed diagnostic products are regulated by the FDA and similar regulatory bodies in other countries and/or regions. Most aspects of development, production, and marketing, including product testing, authorizations to market, labeling, promotion, manufacturing, and record keeping, are subject to regulatory review.

After marketing approval has been granted, the Company must continue to comply with governmental regulations. Failure to comply with applicable requirements can lead to sanctions, including withdrawal of products from the market, recalls, refusal to authorize government contracts, product seizures, civil money penalties, injunctions, and criminal prosecution.

From time to time the Company may become involved in legal proceedings or may be subject to claims arising in the ordinary course of its business. Although the results of litigation and claims cannot be predicted with certainty, the Company currently believes that the final outcome of these ordinary course matters will not have a material adverse effect on its business, operating results, financial condition or cash flows. Regardless of the outcome, litigation can have an adverse impact on the Company because of defense and settlement costs, diversion of management resources, and other factors.

12. Related parties

Related parties with significant interests

Related parties of BioPorto with significant interests include the Board of Directors, the Executive Management, and their close family members. Related parties also include companies in which these persons have control or significant interests.

Transactions with related parties

Other than ordinary executive management and Board of Director remuneration, the company did not have any transactions with related parties in the first nine months of 2025.

13. Subsequent events

On November 13, 2025, the Company announced that a private placement of 40,438,426 new shares has been completed. The gross proceeds for the new shares is approximately DKK 43 million.

BioPorto is an in vitro diagnostics company focused on saving lives and improving the quality of life with actionable biomarkers – tools designed to help clinicians make changes in patient management. The Company uses its expertise in antibodies and assay development, as well as its platform for assay development, to create a pipeline of novel and compelling products that focus on conditions where there is significant unmet medical need, and where the Company's tests can help improve clinical and economic outcomes for patients, providers, and the healthcare ecosystem.

The Company's flagship products are based on the NGAL biomarker and designed to aid in the risk assessment and diagnosis of Acute Kidney Injury, a common clinical syndrome that can have severe consequences, including significant morbidity and mortality, if not identified and treated early. With the aid of NGAL levels, physicians can identify patients potentially at risk of AKI more rapidly than is possible with current standard of care measurements, enabling earlier intervention and more tailored patient management strategies. The Company markets NGAL tests under applicable registrations including CE mark in several countries worldwide.

BioPorto has facilities in Copenhagen, Denmark and Boston, MA, USA. The shares of BioPorto A/S are listed on the Nasdaq Copenhagen stock exchange. For more information visit www.bioporto.com.

www.bioporto.com

BioPorto A/S
Tuborg Havnevej 15, ground floor
DK-2900 Hellerup
Denmark
CVR DK-17500317